$NBIX · NEUROCRINE BIOSCIENCES INC
Neurocrine Biosciences reported Q3 2026 results with total revenue of $1.123B, up 41% year-over-year, driven by INGREZZA ($801M, +17%), CRENESSITY ($211M, +115%), and VYKAT XR ($107M). Non-GAAP diluted EPS was $3.29 versus $2.17 in Q3 2025. The company raised full-year 2026 INGREZZA net product sales guidance to $2.9–$2.925B and lowered GAAP SG&A guidance to $1.54–$1.56B.
- Total Q3 2026 revenue of $1.123B grew 41% YoY from $795M, with net product sales exceeding $1B for the first time.
- INGREZZA Q3 net product sales hit $801M (+17% YoY); full-year 2026 guidance raised to $2.9–$2.925B from $2.825–$2.875B.
- CRENESSITY Q3 net product sales reached $211M (+115% YoY); VYKAT XR contributed $107M in its first full quarter post-Soleno acquisition.
- Non-GAAP diluted EPS of $3.29 vs. $2.17 in Q3 2025; GAAP diluted EPS of $1.96 vs. $2.04, pressured by $52M unrealized loss on equity investments.
- Cash and marketable securities fell to $790M from $2.543B at year-end 2025, reflecting the Soleno Therapeutics acquisition that closed in May 2026.
Extended-hours trading shows NBIX at $153.00, up +5.26% vs the regular close of $145.35, reflecting strong positive reaction to the 41% revenue growth and INGREZZA guidance raise.
Neurocrine crossed $1B in quarterly net product sales for the first time, raised INGREZZA guidance, and now has three growing commercial franchises — a pivotal scale milestone for the biotech.
Neurocrine's diversified portfolio — INGREZZA (TD/Huntington's), CRENESSITY (CAH), and VYKAT XR (Prader-Willi) — now spans three distinct rare/neurological disease franchises, reducing single-product risk. The GLP-1/GIP/glucagon triple agonist entry into obesity signals expansion beyond neuroscience.
Cash reserves dropped from $2.543B to $790M following the Soleno acquisition, which added ~$2.2B in intangible assets now being amortized over 16 years. The $52M unrealized loss on equity investments in Q3 introduces earnings volatility.